BioSpace News Archive

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the initiation of a Phase 2 randomized, double-blind, placebo-controlled, multicenter clinical study – called the “X-NOVA” clinical trial – to evaluate the safety, tolerability, and efficacy of XEN1101 in Major Depressive Disorder (MDD).

Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today announced that enrollment has been completed for the Phase 2 clinical study of bomedemstat for the treatment of essential thrombocythemia (ET) with 73 patients enrolled, exceeding the initial target enrollment of 60 patients.

LianBio’s (Nasdaq: LIAN) partner, Tarsus Pharmaceuticals, Inc. (Tarsus) yesterday announced that TP-03 (lotilaner ophthalmic solution, 0.25%) met the primary endpoint and all secondary endpoints in the Saturn-2 pivotal Phase 3 trial with a favorable safety profile, reinforcing its potential to resolve Demodex blepharitis, a highly prevalent eyelid disease.

Plexium, Inc., a leading next-generation targeted protein degradation company, announced the appointment of Stephen Mullennix as Chief Financial Officer.

Lineage Cell Therapeutics, Inc. today announced that results from the primary endpoint, safety and tolerability 1 year post-transplant, in the ongoing Phase 1/2a clinical study of RG6501 (OpRegen).

Massive Bio, Inc. and Amber Specialty Pharmacy announced its partnership to provide advanced data-driven technology solutions for patient recruitment services to the oncology research ecosystem, and thereby offer better access for cancer patients to leading-edge clinical trials.

Modular Medical, Inc., announced that it has entered into a securities purchase agreement with institutional investor Sio Capital Management in connection with a registered direct offering of an aggregate of 449,438 shares of its common stock at an offering price of $4.45 per share.

Hoth Therapeutics, Inc. today announced the preliminary findings from Hoth’s randomized, double-blind, placebo-controlled Phase 1b study investigating the safety and efficacy of BioLexa Lotion in patients with mild to moderate atopic dermatitis.

Gamida Cell Ltd. today announced that the company will host a conference call and live audio webcast on Tuesday, May 10, 2022, at 8:00 a.m. ET to review its first quarter 2022 financial results and provide an update on the company.

Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, announced that it will present preclinical data for its TN-401 and DWORF gene therapy programs, as well as data on its capsid engineering capabilities at the upcoming American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting.